Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy.

Ling V, Burnett AK, Bradstock K, Seymour JF, Hills RK, Wei A.

Br J Haematol. 2013 Mar;160(6):861-3. doi: 10.1111/bjh.12178. Epub 2012 Dec 24. No abstract available.

PMID:
23278846
2.

One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.

Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, Pigneux A; BGMT Study Group..

Br J Haematol. 2005 May;129(3):403-10.

PMID:
15842665
3.

Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.

Shin HJ, Kim HJ, Sohn SK, Min YH, Won JH, Kim I, Yoon HJ, Lee JH, Jo DY, Joo YD, Jung CW, Lee KH; Korean Society of Hematology, AML/MDS Working Party., Chung JS, Ahn JS, Kim SJ, Lee JH, Choi SJ, Lee JH, Bae SH, Hong DS, Zang DY, Kim SH, Lee JL, Bang SM.

Jpn J Clin Oncol. 2010 Jun;40(6):556-66. doi: 10.1093/jjco/hyq007. Epub 2010 Feb 25.

PMID:
20185460
4.

High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.

Low M, Lee D, Coutsouvelis J, Patil S, Opat S, Walker P, Schwarer A, Salem H, Avery S, Spencer A, Wei A.

Intern Med J. 2013 Mar;43(3):294-7. doi: 10.1111/j.1445-5994.2012.02868.x. Review.

PMID:
22757980
5.

A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.

Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S.

Blood. 1996 Mar 1;87(5):1710-7.

6.

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C; German Acute Myeloid Leukaemia Cooperative Group.; Study Alliance Leukemia Investigators..

Lancet. 2010 Dec 11;376(9757):2000-8. doi: 10.1016/S0140-6736(10)62105-8. Epub 2010 Dec 3.

PMID:
21131036
7.

Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia.

Shpilberg O, Haddad N, Sofer O, Raanani P, Berkowicz M, Chetrit A, Carter A, Ramot B, Tatarski I, Ben-Bassat I.

Leuk Res. 1995 Dec;19(12):893-7.

PMID:
8632657
8.

Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.

Fedele PL, Avery S, Patil S, Spencer A, Haas M, Wei A.

Intern Med J. 2014 Aug;44(8):757-63. doi: 10.1111/imj.12478.

PMID:
24863325
9.

A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.

Valcárcel D, Montesinos P, Sánchez-Ortega I, Brunet S, Esteve J, Martínez-Cuadrón D, Ribera JM, Tormo M, Bueno J, Duarte R, Llorente A, Torres JP, Guardia R, Sanz MA, Sierra AJ; CETLAM Group..

Cancer. 2012 Jan 15;118(2):410-7. doi: 10.1002/cncr.26273. Epub 2011 Jun 29.

10.

Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.

Schaich M, Röllig C, Soucek S, Kramer M, Thiede C, Mohr B, Oelschlaegel U, Schmitz N, Stuhlmann R, Wandt H, Schäfer-Eckart K, Aulitzky W, Kaufmann M, Bodenstein H, Tischler J, Ho A, Krämer A, Bornhäuser M, Schetelig J, Ehninger G.

J Clin Oncol. 2011 Jul 1;29(19):2696-702. doi: 10.1200/JCO.2010.33.7303. Epub 2011 May 23.

PMID:
21606413
11.

Chemotherapy of adult acute myeloid leukaemia.

Suri R, Kueh YK, Han P, Tan YO.

Ann Acad Med Singapore. 1990 Mar;19(2):175-7.

PMID:
2346291
12.

Relapse and death during first remission in acute myeloid leukemia.

Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E.

Haematologica. 2008 Apr;93(4):633-4. doi: 10.3324/haematol.12366. No abstract available.

13.

Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.

Grigg AP, Reynolds J, McQuillan A, Juneja SK, Di Iulio J, Hui C, Smith C, Kimber R, Bradstock KF; Australasian Leukaemia and Lymphoma Group..

Leuk Lymphoma. 2005 Mar;46(3):367-75.

PMID:
15621826
14.

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA.

Blood. 2005 May 1;105(9):3420-7. Epub 2004 Nov 30.

15.

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.

Löwenberg B.

Blood. 2013 Jan 3;121(1):26-8. doi: 10.1182/blood-2012-07-444851. Review.

16.

A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).

Lowenthal RM, Bradstock KF, Matthews JP, Bishop JF, Juneja S, Cobcroft R, Eliadis P, Enno A, Gill D, Herrmann RP, Manoharan A, Page FJ, Rooney KF, Rosenfeld D, Seldon M, Taylor KM, Wolf MM, Young GA.

Leuk Lymphoma. 1999 Aug;34(5-6):501-10.

PMID:
10492073
17.

Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.

Liu J, Mi Y, Fu M, Yu W, Wang Y, Lin D, Bian S, Wang J.

Am J Hematol. 2009 Jul;84(7):422-7. doi: 10.1002/ajh.21441.

18.

Outcome of acute myeloid leukaemia in adults: a retrospective analysis.

Saikia TK, Bakshi A, Bhagwat R, Tawde S, Nair R, Nair CN, Parikh PM.

Natl Med J India. 2005 Jan-Feb;18(1):12-5.

PMID:
15835484
19.

Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

Pigneux A, Harousseau JL, Witz F, Sauvezie M, Bene MC, Luquet I, Hunault-Berger M, Recher C, Lioure B, Himberlin C, Escoffre-Barbe M, Berthou C, Lissandre S, Fegueux N, Cahn JY, Jourdan E, Dreyfus F, Reiffers J, Milpied N, Ifrah N.

J Clin Oncol. 2010 Jun 20;28(18):3028-34. doi: 10.1200/JCO.2009.26.4648. Epub 2010 May 17.

PMID:
20479424
20.

A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.

Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R.

Blood. 2011 Feb 24;117(8):2366-72. doi: 10.1182/blood-2010-07-295279. Epub 2010 Dec 29.

Supplemental Content

Support Center